nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosinopril—ACE—umbilical vein—urinary bladder cancer	0.0379	0.188	CbGeAlD
Fosinopril—ACE—urine—urinary bladder cancer	0.0305	0.152	CbGeAlD
Fosinopril—Mitiglinide—UGT2B7—urinary bladder cancer	0.0127	0.719	CrCbGaD
Fosinopril—SLC15A1—epithelium—urinary bladder cancer	0.0112	0.0558	CbGeAlD
Fosinopril—ACE—prostate gland—urinary bladder cancer	0.011	0.0544	CbGeAlD
Fosinopril—SLC15A1—renal system—urinary bladder cancer	0.0104	0.0517	CbGeAlD
Fosinopril—SLC15A2—prostate gland—urinary bladder cancer	0.00956	0.0474	CbGeAlD
Fosinopril—ACE—seminal vesicle—urinary bladder cancer	0.00927	0.046	CbGeAlD
Fosinopril—SLC15A2—seminal vesicle—urinary bladder cancer	0.00809	0.0401	CbGeAlD
Fosinopril—ACE—epithelium—urinary bladder cancer	0.00806	0.04	CbGeAlD
Fosinopril—ACE—smooth muscle tissue—urinary bladder cancer	0.00776	0.0385	CbGeAlD
Fosinopril—SLC15A1—vagina—urinary bladder cancer	0.00755	0.0375	CbGeAlD
Fosinopril—ACE—renal system—urinary bladder cancer	0.00747	0.0371	CbGeAlD
Fosinopril—ACE—urethra—urinary bladder cancer	0.00734	0.0364	CbGeAlD
Fosinopril—SLC15A2—renal system—urinary bladder cancer	0.00652	0.0323	CbGeAlD
Fosinopril—SLC15A2—urethra—urinary bladder cancer	0.0064	0.0318	CbGeAlD
Fosinopril—ACE—female reproductive system—urinary bladder cancer	0.00599	0.0297	CbGeAlD
Fosinopril—SLC15A2—female reproductive system—urinary bladder cancer	0.00522	0.0259	CbGeAlD
Fosinopril—Mitiglinide—PPARG—urinary bladder cancer	0.00497	0.281	CrCbGaD
Fosinopril—SLC15A2—vagina—urinary bladder cancer	0.00472	0.0234	CbGeAlD
Fosinopril—ACE—lymph node—urinary bladder cancer	0.0035	0.0174	CbGeAlD
Fosinopril—SLC15A2—lymph node—urinary bladder cancer	0.00305	0.0151	CbGeAlD
Fosinopril—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000449	0.000576	CcSEcCtD
Fosinopril—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000449	0.000575	CcSEcCtD
Fosinopril—Haemoglobin—Methotrexate—urinary bladder cancer	0.000449	0.000575	CcSEcCtD
Fosinopril—Haemorrhage—Methotrexate—urinary bladder cancer	0.000447	0.000572	CcSEcCtD
Fosinopril—Hepatitis—Methotrexate—urinary bladder cancer	0.000447	0.000572	CcSEcCtD
Fosinopril—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000446	0.000572	CcSEcCtD
Fosinopril—Asthenia—Gemcitabine—urinary bladder cancer	0.000445	0.00057	CcSEcCtD
Fosinopril—Pharyngitis—Methotrexate—urinary bladder cancer	0.000443	0.000568	CcSEcCtD
Fosinopril—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000441	0.000565	CcSEcCtD
Fosinopril—Weight increased—Doxorubicin—urinary bladder cancer	0.00044	0.000563	CcSEcCtD
Fosinopril—Epistaxis—Epirubicin—urinary bladder cancer	0.000439	0.000563	CcSEcCtD
Fosinopril—Pruritus—Gemcitabine—urinary bladder cancer	0.000439	0.000562	CcSEcCtD
Fosinopril—Nausea—Thiotepa—urinary bladder cancer	0.000438	0.000561	CcSEcCtD
Fosinopril—Weight decreased—Doxorubicin—urinary bladder cancer	0.000437	0.00056	CcSEcCtD
Fosinopril—Sinusitis—Epirubicin—urinary bladder cancer	0.000437	0.00056	CcSEcCtD
Fosinopril—Feeling abnormal—Etoposide—urinary bladder cancer	0.000437	0.000559	CcSEcCtD
Fosinopril—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000435	0.000557	CcSEcCtD
Fosinopril—Pneumonia—Doxorubicin—urinary bladder cancer	0.000433	0.000555	CcSEcCtD
Fosinopril—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000433	0.000555	CcSEcCtD
Fosinopril—Pruritus—Fluorouracil—urinary bladder cancer	0.000432	0.000553	CcSEcCtD
Fosinopril—Drowsiness—Doxorubicin—urinary bladder cancer	0.000431	0.000552	CcSEcCtD
Fosinopril—Visual impairment—Methotrexate—urinary bladder cancer	0.00043	0.000551	CcSEcCtD
Fosinopril—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000427	0.000547	CcSEcCtD
Fosinopril—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000426	0.000546	CcSEcCtD
Fosinopril—Bradycardia—Epirubicin—urinary bladder cancer	0.000426	0.000545	CcSEcCtD
Fosinopril—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000425	0.000544	CcSEcCtD
Fosinopril—Renal failure—Doxorubicin—urinary bladder cancer	0.000424	0.000543	CcSEcCtD
Fosinopril—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000422	0.000541	CcSEcCtD
Fosinopril—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000422	0.000541	CcSEcCtD
Fosinopril—Urticaria—Etoposide—urinary bladder cancer	0.000421	0.000539	CcSEcCtD
Fosinopril—Haemoglobin—Epirubicin—urinary bladder cancer	0.00042	0.000538	CcSEcCtD
Fosinopril—Jaundice—Doxorubicin—urinary bladder cancer	0.00042	0.000538	CcSEcCtD
Fosinopril—Rhinitis—Epirubicin—urinary bladder cancer	0.000419	0.000537	CcSEcCtD
Fosinopril—Abdominal pain—Etoposide—urinary bladder cancer	0.000419	0.000536	CcSEcCtD
Fosinopril—Body temperature increased—Etoposide—urinary bladder cancer	0.000419	0.000536	CcSEcCtD
Fosinopril—Haemorrhage—Epirubicin—urinary bladder cancer	0.000418	0.000535	CcSEcCtD
Fosinopril—Hepatitis—Epirubicin—urinary bladder cancer	0.000418	0.000535	CcSEcCtD
Fosinopril—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000417	0.000535	CcSEcCtD
Fosinopril—Tinnitus—Methotrexate—urinary bladder cancer	0.000416	0.000533	CcSEcCtD
Fosinopril—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000416	0.000533	CcSEcCtD
Fosinopril—Asthenia—Cisplatin—urinary bladder cancer	0.000415	0.000531	CcSEcCtD
Fosinopril—Pharyngitis—Epirubicin—urinary bladder cancer	0.000415	0.000531	CcSEcCtD
Fosinopril—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000412	0.000527	CcSEcCtD
Fosinopril—Epistaxis—Doxorubicin—urinary bladder cancer	0.000406	0.000521	CcSEcCtD
Fosinopril—Sinusitis—Doxorubicin—urinary bladder cancer	0.000404	0.000518	CcSEcCtD
Fosinopril—Dizziness—Fluorouracil—urinary bladder cancer	0.000403	0.000517	CcSEcCtD
Fosinopril—Visual impairment—Epirubicin—urinary bladder cancer	0.000403	0.000516	CcSEcCtD
Fosinopril—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000402	0.000515	CcSEcCtD
Fosinopril—Chills—Methotrexate—urinary bladder cancer	0.000401	0.000513	CcSEcCtD
Fosinopril—Diarrhoea—Cisplatin—urinary bladder cancer	0.000396	0.000507	CcSEcCtD
Fosinopril—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000395	0.000506	CcSEcCtD
Fosinopril—Vomiting—Gemcitabine—urinary bladder cancer	0.000395	0.000505	CcSEcCtD
Fosinopril—Bradycardia—Doxorubicin—urinary bladder cancer	0.000394	0.000504	CcSEcCtD
Fosinopril—Rash—Gemcitabine—urinary bladder cancer	0.000391	0.000501	CcSEcCtD
Fosinopril—Dermatitis—Gemcitabine—urinary bladder cancer	0.000391	0.000501	CcSEcCtD
Fosinopril—Hypersensitivity—Etoposide—urinary bladder cancer	0.00039	0.0005	CcSEcCtD
Fosinopril—Tinnitus—Epirubicin—urinary bladder cancer	0.00039	0.000499	CcSEcCtD
Fosinopril—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000389	0.000498	CcSEcCtD
Fosinopril—Headache—Gemcitabine—urinary bladder cancer	0.000389	0.000498	CcSEcCtD
Fosinopril—Flushing—Epirubicin—urinary bladder cancer	0.000388	0.000497	CcSEcCtD
Fosinopril—Vomiting—Fluorouracil—urinary bladder cancer	0.000388	0.000497	CcSEcCtD
Fosinopril—Rhinitis—Doxorubicin—urinary bladder cancer	0.000388	0.000497	CcSEcCtD
Fosinopril—Hepatitis—Doxorubicin—urinary bladder cancer	0.000387	0.000495	CcSEcCtD
Fosinopril—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000387	0.000495	CcSEcCtD
Fosinopril—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000385	0.000493	CcSEcCtD
Fosinopril—Rash—Fluorouracil—urinary bladder cancer	0.000385	0.000493	CcSEcCtD
Fosinopril—Dermatitis—Fluorouracil—urinary bladder cancer	0.000384	0.000492	CcSEcCtD
Fosinopril—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000384	0.000492	CcSEcCtD
Fosinopril—Headache—Fluorouracil—urinary bladder cancer	0.000382	0.00049	CcSEcCtD
Fosinopril—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000381	0.000488	CcSEcCtD
Fosinopril—Dysgeusia—Methotrexate—urinary bladder cancer	0.000381	0.000488	CcSEcCtD
Fosinopril—Asthenia—Etoposide—urinary bladder cancer	0.00038	0.000487	CcSEcCtD
Fosinopril—Chills—Epirubicin—urinary bladder cancer	0.000375	0.00048	CcSEcCtD
Fosinopril—Pruritus—Etoposide—urinary bladder cancer	0.000375	0.00048	CcSEcCtD
Fosinopril—Arrhythmia—Epirubicin—urinary bladder cancer	0.000373	0.000478	CcSEcCtD
Fosinopril—Visual impairment—Doxorubicin—urinary bladder cancer	0.000373	0.000477	CcSEcCtD
Fosinopril—Nausea—Gemcitabine—urinary bladder cancer	0.000369	0.000472	CcSEcCtD
Fosinopril—Vomiting—Cisplatin—urinary bladder cancer	0.000368	0.000471	CcSEcCtD
Fosinopril—Vision blurred—Methotrexate—urinary bladder cancer	0.000366	0.000469	CcSEcCtD
Fosinopril—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000366	0.000468	CcSEcCtD
Fosinopril—Rash—Cisplatin—urinary bladder cancer	0.000365	0.000467	CcSEcCtD
Fosinopril—Dermatitis—Cisplatin—urinary bladder cancer	0.000364	0.000467	CcSEcCtD
Fosinopril—Diarrhoea—Etoposide—urinary bladder cancer	0.000363	0.000464	CcSEcCtD
Fosinopril—Nausea—Fluorouracil—urinary bladder cancer	0.000362	0.000464	CcSEcCtD
Fosinopril—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000361	0.000462	CcSEcCtD
Fosinopril—Tinnitus—Doxorubicin—urinary bladder cancer	0.000361	0.000462	CcSEcCtD
Fosinopril—Anaemia—Methotrexate—urinary bladder cancer	0.000359	0.00046	CcSEcCtD
Fosinopril—Flushing—Doxorubicin—urinary bladder cancer	0.000359	0.00046	CcSEcCtD
Fosinopril—Flatulence—Epirubicin—urinary bladder cancer	0.000359	0.000459	CcSEcCtD
Fosinopril—Tension—Epirubicin—urinary bladder cancer	0.000357	0.000457	CcSEcCtD
Fosinopril—Dysgeusia—Epirubicin—urinary bladder cancer	0.000356	0.000456	CcSEcCtD
Fosinopril—Nervousness—Epirubicin—urinary bladder cancer	0.000353	0.000453	CcSEcCtD
Fosinopril—Malaise—Methotrexate—urinary bladder cancer	0.000351	0.000449	CcSEcCtD
Fosinopril—Dizziness—Etoposide—urinary bladder cancer	0.00035	0.000449	CcSEcCtD
Fosinopril—Muscle spasms—Epirubicin—urinary bladder cancer	0.00035	0.000448	CcSEcCtD
Fosinopril—Vertigo—Methotrexate—urinary bladder cancer	0.000349	0.000448	CcSEcCtD
Fosinopril—Leukopenia—Methotrexate—urinary bladder cancer	0.000348	0.000446	CcSEcCtD
Fosinopril—Chills—Doxorubicin—urinary bladder cancer	0.000347	0.000445	CcSEcCtD
Fosinopril—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000346	0.000443	CcSEcCtD
Fosinopril—Nausea—Cisplatin—urinary bladder cancer	0.000344	0.00044	CcSEcCtD
Fosinopril—Vision blurred—Epirubicin—urinary bladder cancer	0.000343	0.000439	CcSEcCtD
Fosinopril—Cough—Methotrexate—urinary bladder cancer	0.000339	0.000435	CcSEcCtD
Fosinopril—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000338	0.000432	CcSEcCtD
Fosinopril—Vomiting—Etoposide—urinary bladder cancer	0.000337	0.000431	CcSEcCtD
Fosinopril—Anaemia—Epirubicin—urinary bladder cancer	0.000336	0.000431	CcSEcCtD
Fosinopril—Agitation—Epirubicin—urinary bladder cancer	0.000334	0.000428	CcSEcCtD
Fosinopril—Rash—Etoposide—urinary bladder cancer	0.000334	0.000428	CcSEcCtD
Fosinopril—Dermatitis—Etoposide—urinary bladder cancer	0.000334	0.000428	CcSEcCtD
Fosinopril—Headache—Etoposide—urinary bladder cancer	0.000332	0.000425	CcSEcCtD
Fosinopril—Flatulence—Doxorubicin—urinary bladder cancer	0.000332	0.000425	CcSEcCtD
Fosinopril—Arthralgia—Methotrexate—urinary bladder cancer	0.000331	0.000424	CcSEcCtD
Fosinopril—Chest pain—Methotrexate—urinary bladder cancer	0.000331	0.000424	CcSEcCtD
Fosinopril—Myalgia—Methotrexate—urinary bladder cancer	0.000331	0.000424	CcSEcCtD
Fosinopril—Tension—Doxorubicin—urinary bladder cancer	0.00033	0.000423	CcSEcCtD
Fosinopril—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00033	0.000422	CcSEcCtD
Fosinopril—Malaise—Epirubicin—urinary bladder cancer	0.000328	0.00042	CcSEcCtD
Fosinopril—Discomfort—Methotrexate—urinary bladder cancer	0.000327	0.000419	CcSEcCtD
Fosinopril—Nervousness—Doxorubicin—urinary bladder cancer	0.000327	0.000419	CcSEcCtD
Fosinopril—Vertigo—Epirubicin—urinary bladder cancer	0.000327	0.000419	CcSEcCtD
Fosinopril—Syncope—Epirubicin—urinary bladder cancer	0.000326	0.000418	CcSEcCtD
Fosinopril—Leukopenia—Epirubicin—urinary bladder cancer	0.000326	0.000417	CcSEcCtD
Fosinopril—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000324	0.000415	CcSEcCtD
Fosinopril—Palpitations—Epirubicin—urinary bladder cancer	0.000322	0.000412	CcSEcCtD
Fosinopril—Confusional state—Methotrexate—urinary bladder cancer	0.00032	0.00041	CcSEcCtD
Fosinopril—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00032	0.00041	CcSEcCtD
Fosinopril—Cough—Epirubicin—urinary bladder cancer	0.000318	0.000407	CcSEcCtD
Fosinopril—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000317	0.000407	CcSEcCtD
Fosinopril—Vision blurred—Doxorubicin—urinary bladder cancer	0.000317	0.000406	CcSEcCtD
Fosinopril—Infection—Methotrexate—urinary bladder cancer	0.000315	0.000404	CcSEcCtD
Fosinopril—Nausea—Etoposide—urinary bladder cancer	0.000315	0.000403	CcSEcCtD
Fosinopril—Hypertension—Epirubicin—urinary bladder cancer	0.000314	0.000402	CcSEcCtD
Fosinopril—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000312	0.0004	CcSEcCtD
Fosinopril—Anaemia—Doxorubicin—urinary bladder cancer	0.000311	0.000399	CcSEcCtD
Fosinopril—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000311	0.000398	CcSEcCtD
Fosinopril—Myalgia—Epirubicin—urinary bladder cancer	0.00031	0.000397	CcSEcCtD
Fosinopril—Chest pain—Epirubicin—urinary bladder cancer	0.00031	0.000397	CcSEcCtD
Fosinopril—Arthralgia—Epirubicin—urinary bladder cancer	0.00031	0.000397	CcSEcCtD
Fosinopril—Agitation—Doxorubicin—urinary bladder cancer	0.000309	0.000396	CcSEcCtD
Fosinopril—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000307	0.000393	CcSEcCtD
Fosinopril—Discomfort—Epirubicin—urinary bladder cancer	0.000306	0.000392	CcSEcCtD
Fosinopril—Malaise—Doxorubicin—urinary bladder cancer	0.000304	0.000389	CcSEcCtD
Fosinopril—Dry mouth—Epirubicin—urinary bladder cancer	0.000303	0.000388	CcSEcCtD
Fosinopril—Vertigo—Doxorubicin—urinary bladder cancer	0.000303	0.000387	CcSEcCtD
Fosinopril—Anorexia—Methotrexate—urinary bladder cancer	0.000303	0.000387	CcSEcCtD
Fosinopril—Syncope—Doxorubicin—urinary bladder cancer	0.000302	0.000387	CcSEcCtD
Fosinopril—Leukopenia—Doxorubicin—urinary bladder cancer	0.000301	0.000386	CcSEcCtD
Fosinopril—Confusional state—Epirubicin—urinary bladder cancer	0.000299	0.000384	CcSEcCtD
Fosinopril—Palpitations—Doxorubicin—urinary bladder cancer	0.000298	0.000381	CcSEcCtD
Fosinopril—Oedema—Epirubicin—urinary bladder cancer	0.000297	0.00038	CcSEcCtD
Fosinopril—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000297	0.00038	CcSEcCtD
Fosinopril—Hypotension—Methotrexate—urinary bladder cancer	0.000297	0.00038	CcSEcCtD
Fosinopril—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000296	0.000379	CcSEcCtD
Fosinopril—Infection—Epirubicin—urinary bladder cancer	0.000295	0.000378	CcSEcCtD
Fosinopril—Cough—Doxorubicin—urinary bladder cancer	0.000294	0.000376	CcSEcCtD
Fosinopril—Shock—Epirubicin—urinary bladder cancer	0.000292	0.000374	CcSEcCtD
Fosinopril—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000291	0.000372	CcSEcCtD
Fosinopril—Hypertension—Doxorubicin—urinary bladder cancer	0.000291	0.000372	CcSEcCtD
Fosinopril—Tachycardia—Epirubicin—urinary bladder cancer	0.00029	0.000371	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000289	0.00037	CcSEcCtD
Fosinopril—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000287	0.000368	CcSEcCtD
Fosinopril—Insomnia—Methotrexate—urinary bladder cancer	0.000287	0.000368	CcSEcCtD
Fosinopril—Myalgia—Doxorubicin—urinary bladder cancer	0.000287	0.000367	CcSEcCtD
Fosinopril—Chest pain—Doxorubicin—urinary bladder cancer	0.000287	0.000367	CcSEcCtD
Fosinopril—Arthralgia—Doxorubicin—urinary bladder cancer	0.000287	0.000367	CcSEcCtD
Fosinopril—Paraesthesia—Methotrexate—urinary bladder cancer	0.000285	0.000365	CcSEcCtD
Fosinopril—Discomfort—Doxorubicin—urinary bladder cancer	0.000283	0.000363	CcSEcCtD
Fosinopril—Anorexia—Epirubicin—urinary bladder cancer	0.000283	0.000363	CcSEcCtD
Fosinopril—Dyspnoea—Methotrexate—urinary bladder cancer	0.000283	0.000362	CcSEcCtD
Fosinopril—Somnolence—Methotrexate—urinary bladder cancer	0.000282	0.000361	CcSEcCtD
Fosinopril—Dry mouth—Doxorubicin—urinary bladder cancer	0.00028	0.000359	CcSEcCtD
Fosinopril—Dyspepsia—Methotrexate—urinary bladder cancer	0.000279	0.000358	CcSEcCtD
Fosinopril—Hypotension—Epirubicin—urinary bladder cancer	0.000278	0.000355	CcSEcCtD
Fosinopril—Confusional state—Doxorubicin—urinary bladder cancer	0.000277	0.000355	CcSEcCtD
Fosinopril—Decreased appetite—Methotrexate—urinary bladder cancer	0.000276	0.000353	CcSEcCtD
Fosinopril—Oedema—Doxorubicin—urinary bladder cancer	0.000275	0.000352	CcSEcCtD
Fosinopril—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000275	0.000352	CcSEcCtD
Fosinopril—Fatigue—Methotrexate—urinary bladder cancer	0.000274	0.00035	CcSEcCtD
Fosinopril—Infection—Doxorubicin—urinary bladder cancer	0.000273	0.00035	CcSEcCtD
Fosinopril—Pain—Methotrexate—urinary bladder cancer	0.000271	0.000348	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000271	0.000347	CcSEcCtD
Fosinopril—Shock—Doxorubicin—urinary bladder cancer	0.00027	0.000346	CcSEcCtD
Fosinopril—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000269	0.000345	CcSEcCtD
Fosinopril—Insomnia—Epirubicin—urinary bladder cancer	0.000269	0.000344	CcSEcCtD
Fosinopril—Tachycardia—Doxorubicin—urinary bladder cancer	0.000268	0.000344	CcSEcCtD
Fosinopril—Paraesthesia—Epirubicin—urinary bladder cancer	0.000267	0.000342	CcSEcCtD
Fosinopril—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000266	0.00034	CcSEcCtD
Fosinopril—Dyspnoea—Epirubicin—urinary bladder cancer	0.000265	0.000339	CcSEcCtD
Fosinopril—Somnolence—Epirubicin—urinary bladder cancer	0.000264	0.000338	CcSEcCtD
Fosinopril—Anorexia—Doxorubicin—urinary bladder cancer	0.000262	0.000336	CcSEcCtD
Fosinopril—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000262	0.000335	CcSEcCtD
Fosinopril—Dyspepsia—Epirubicin—urinary bladder cancer	0.000261	0.000335	CcSEcCtD
Fosinopril—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00026	0.000332	CcSEcCtD
Fosinopril—Decreased appetite—Epirubicin—urinary bladder cancer	0.000258	0.000331	CcSEcCtD
Fosinopril—Hypotension—Doxorubicin—urinary bladder cancer	0.000257	0.000329	CcSEcCtD
Fosinopril—Fatigue—Epirubicin—urinary bladder cancer	0.000256	0.000328	CcSEcCtD
Fosinopril—Pain—Epirubicin—urinary bladder cancer	0.000254	0.000325	CcSEcCtD
Fosinopril—Constipation—Epirubicin—urinary bladder cancer	0.000254	0.000325	CcSEcCtD
Fosinopril—Urticaria—Methotrexate—urinary bladder cancer	0.000252	0.000323	CcSEcCtD
Fosinopril—Abdominal pain—Methotrexate—urinary bladder cancer	0.000251	0.000321	CcSEcCtD
Fosinopril—Body temperature increased—Methotrexate—urinary bladder cancer	0.000251	0.000321	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00025	0.000321	CcSEcCtD
Fosinopril—Insomnia—Doxorubicin—urinary bladder cancer	0.000249	0.000318	CcSEcCtD
Fosinopril—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000247	0.000316	CcSEcCtD
Fosinopril—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000245	0.000314	CcSEcCtD
Fosinopril—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000245	0.000313	CcSEcCtD
Fosinopril—Somnolence—Doxorubicin—urinary bladder cancer	0.000244	0.000313	CcSEcCtD
Fosinopril—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000243	0.000311	CcSEcCtD
Fosinopril—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000242	0.00031	CcSEcCtD
Fosinopril—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000239	0.000306	CcSEcCtD
Fosinopril—Fatigue—Doxorubicin—urinary bladder cancer	0.000237	0.000303	CcSEcCtD
Fosinopril—Urticaria—Epirubicin—urinary bladder cancer	0.000236	0.000302	CcSEcCtD
Fosinopril—Constipation—Doxorubicin—urinary bladder cancer	0.000235	0.000301	CcSEcCtD
Fosinopril—Pain—Doxorubicin—urinary bladder cancer	0.000235	0.000301	CcSEcCtD
Fosinopril—Abdominal pain—Epirubicin—urinary bladder cancer	0.000235	0.000301	CcSEcCtD
Fosinopril—Body temperature increased—Epirubicin—urinary bladder cancer	0.000235	0.000301	CcSEcCtD
Fosinopril—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000234	0.000299	CcSEcCtD
Fosinopril—Asthenia—Methotrexate—urinary bladder cancer	0.000228	0.000292	CcSEcCtD
Fosinopril—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000226	0.00029	CcSEcCtD
Fosinopril—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000225	0.000288	CcSEcCtD
Fosinopril—Pruritus—Methotrexate—urinary bladder cancer	0.000225	0.000288	CcSEcCtD
Fosinopril—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000219	0.00028	CcSEcCtD
Fosinopril—Urticaria—Doxorubicin—urinary bladder cancer	0.000218	0.00028	CcSEcCtD
Fosinopril—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000217	0.000278	CcSEcCtD
Fosinopril—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000217	0.000278	CcSEcCtD
Fosinopril—Diarrhoea—Methotrexate—urinary bladder cancer	0.000217	0.000278	CcSEcCtD
Fosinopril—Asthenia—Epirubicin—urinary bladder cancer	0.000213	0.000273	CcSEcCtD
Fosinopril—Pruritus—Epirubicin—urinary bladder cancer	0.00021	0.000269	CcSEcCtD
Fosinopril—Dizziness—Methotrexate—urinary bladder cancer	0.00021	0.000269	CcSEcCtD
Fosinopril—Diarrhoea—Epirubicin—urinary bladder cancer	0.000203	0.00026	CcSEcCtD
Fosinopril—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000202	0.000259	CcSEcCtD
Fosinopril—Vomiting—Methotrexate—urinary bladder cancer	0.000202	0.000258	CcSEcCtD
Fosinopril—Rash—Methotrexate—urinary bladder cancer	0.0002	0.000256	CcSEcCtD
Fosinopril—Dermatitis—Methotrexate—urinary bladder cancer	0.0002	0.000256	CcSEcCtD
Fosinopril—Headache—Methotrexate—urinary bladder cancer	0.000199	0.000255	CcSEcCtD
Fosinopril—Asthenia—Doxorubicin—urinary bladder cancer	0.000197	0.000253	CcSEcCtD
Fosinopril—Dizziness—Epirubicin—urinary bladder cancer	0.000196	0.000252	CcSEcCtD
Fosinopril—Pruritus—Doxorubicin—urinary bladder cancer	0.000194	0.000249	CcSEcCtD
Fosinopril—Vomiting—Epirubicin—urinary bladder cancer	0.000189	0.000242	CcSEcCtD
Fosinopril—Nausea—Methotrexate—urinary bladder cancer	0.000189	0.000241	CcSEcCtD
Fosinopril—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000188	0.000241	CcSEcCtD
Fosinopril—Rash—Epirubicin—urinary bladder cancer	0.000187	0.00024	CcSEcCtD
Fosinopril—Dermatitis—Epirubicin—urinary bladder cancer	0.000187	0.00024	CcSEcCtD
Fosinopril—Headache—Epirubicin—urinary bladder cancer	0.000186	0.000238	CcSEcCtD
Fosinopril—Dizziness—Doxorubicin—urinary bladder cancer	0.000182	0.000233	CcSEcCtD
Fosinopril—Nausea—Epirubicin—urinary bladder cancer	0.000176	0.000226	CcSEcCtD
Fosinopril—Vomiting—Doxorubicin—urinary bladder cancer	0.000175	0.000224	CcSEcCtD
Fosinopril—Rash—Doxorubicin—urinary bladder cancer	0.000173	0.000222	CcSEcCtD
Fosinopril—Dermatitis—Doxorubicin—urinary bladder cancer	0.000173	0.000222	CcSEcCtD
Fosinopril—Headache—Doxorubicin—urinary bladder cancer	0.000172	0.000221	CcSEcCtD
Fosinopril—Nausea—Doxorubicin—urinary bladder cancer	0.000163	0.000209	CcSEcCtD
